CELC gets approval; commercial launch planned this quarter
REVTORPYK was approved for second-line metastatic breast cancer. A commercial launch is planned for this quarter, while a supplemental NDA for PIK3CA-mutant patients is under review.
REVTORPYK received approval for second-line metastatic breast cancer, with a commercial launch planned this quarter. A supplemental NDA for PIK3CA mutant patients is under review. Two phase III breast cancer studies and a prostate cancer trial are ongoing, with strong efficacy and flexible regimens reported.